Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 DDI with Ritonavir and Itraconazole in Advanced Breast Cancer
NCT06710990Phase 1Completed
- Sponsor
- Hengrui
- Start
- Feb 2025
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of trastuzumab rezetecan in breast cancer (2 cohorts), sponsored by Hengrui. Primary endpoints: Maximum concentration for SHR-A1811 at Cycle 3, Maximum concentration for payload at Cycle 3 and 2 more. Started Feb 2025; status: completed.
02
Drugs
trastuzumab rezetecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06710990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06710990.